黑色素瘤获得MAPKi耐药性的非基因组和免疫进化
Willy Hugo1, Hubing Shi1, Lu Sun1
1Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA.
Cell
|September 12, 2015
概括
黑色素瘤通过非基因组变化和免疫系统变化对向治疗产生抗性. 这些变化会影响治疗的有效性和对免疫治疗的潜在反应.
科学领域:
- 癌症学
- 免疫学
- 基因组学
背景情况:
- 在黑色素瘤中对MAPK抑制剂 (MAPKi) 治疗获得的耐药性并不能完全由遗传突变解释.
- 瘤免疫可能与耐药性共同发展,影响治疗结果.
研究的目的:
- 确定黑色素瘤中获得的MAPKi耐药性的非基因机制.
- 在耐药性发展过程中描述瘤内免疫组成的动态变化.
主要方法:
- 在治疗前和进展过程中对患者匹配的黑色素瘤进行比较的转录和甲基分析.
- 分析的重点是确定反复发生的非基因组变异和免疫细胞动态.
主要成果:
- 与DNA甲基化变化相关的反复转录基因变化被确定为耐药性的驱动因素.
- 关键的非基因组驱动因素包括增加的c-MET表达,减少的LEF1表达和YAP1特征丰富.
- 在某些情况下,先前存在的高瘤内T细胞炎症导致CD8T细胞耗尽和抗原呈现受损,这表明免疫治疗可能存在交叉耐药性.
结论:
- 黑色素瘤通过动态,反复的非基因组变化获得MAPKi耐药性.
- 同进化的瘤内免疫在耐药性中起着至关重要的作用,并可能预测随后的免疫疗法的反应.
相关概念视频
Mismatch Repair
7.0K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
7.0K
MAPK Signaling Cascades
9.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.3K
Adaptive Mechanisms in Cancer Cells
7.4K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Adaptive Mechanisms in Cancer Cells
4.3K
4.3K
Mouse Models of Cancer Study
6.7K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.7K
mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K


